Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis

Antiviral Therapy

Volumn 10, Issue 8, 2005, Pages 937-943

  Autar, Reshma S ^a,b   Wit, Ferdinand W N M ^b   Sankote, Jongkol ^a   Mahanontharit, Apicha ^a   Anekthananon, Thanomsak ^c   Mootsikapun, Piroon ^d   Sujaikaew, Khanjtta ^a   Cooper, David A ^e,f   Lange, Joep M A ^b,g   Phanuphak, Praphan ^a,h   Ruxrungtham, Kiat ^a,h   Burger, David M ⁱ  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MAHIDOL UNIVERSITY   (Thailand)

^d KHON KAEN UNIVERSITY   (Thailand)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g PharmAccess International   (Netherlands)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; FLUCONAZOLE; GPO VIR S30; GPO VIR S40; ISONIAZID; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VITAMIN B COMPLEX; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUPERINFECTION; THAILAND; TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEVIRAPINE; RIFAMPIN; THAILAND; TUBERCULOSIS;

EID: 30444444706     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Smith PF, DiCenzo R & Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clinical Pharmacokinetics 2001; 40:893-905.
2. Finch CK, Chrisman CR, Baciewicz AM & Self TH. Rifampin and rifabutin drug interactions: an update. Archives of Internal Medicine 2002; 162:985-992.
3. Gallicano KD, Sahai T, Shukla VK, Seguin I, Pakuts A Kwok D, Foster BC & Cameron DW. Induction of zidovudine glucuronidation and animation pathways by rifampicin in HIV-infected patients. British Journal of Clinical Pharmacology 1999; 48:168-179.
4. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liegeois F, Nerrienet E, Tardy M, Peeters M, Andneux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngole E & Delaporte E. Effectiveness and safety of a generic fixed-dose combination of nevirajpine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34.
5. Centers for Disease Control and Prevention (CDC). MMWR Recommendations and Reports. Treatment of tuberculosis. 2003; 1-77/52(RR11). Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm. (last accessed: 26 September 2005).
6. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, Ruiz I & Pahissa A. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. Journal of Acquired Immune Deficiency Syndromes 2001; 28:450-453.
7. Robinson P, Lamson M, Gigliotti M & Myers M. Pharmacokinetic interaction between nevirapine and rifampicin. XIIth International Conference on AIDS. 28 June-3 July 1998, Geneva, Switzerland. Abstract 60623.
8. Viramune Prescribing Information, Boehringer Ingelheim Pharmaceuticals Inc, January 2004.
9. Viramune Summary of Product Characteristics, Boehringer Ingelheim International GmbH, February 2004.
10. van Leth F, Kappelhoff B, Johnson D, Losso M, Boron-Kaczmarska A, Saag M, Livrozet JM, Hall D, Huitema A, Wit F, Beijnen J, Lange J & the 2NN Study Group. Minimum plasma concentrations of nevirapine and efavirenz in relation to virologic failure in antiretroviral-naive patients. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 80.
11. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH & Hoetelmans RM. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-1095.
12. van Leth F, Hall D & Lange J. Regional differences in treatment failure in the 2NN study. 7th International Congress on Drug Therapy in HIV Infection. November 14-18 2004, Glasgow, United Kingdom. Abstract PL7.4.
13. Droste JA, Verweij-Van Wissen CP & Burger DM. Simultaneous determination of the HIV drugs indinavin amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelrinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 2003; 25:393-399.
14. Droste TA, Aarnoutse RE, Koopmans PP, Hekster YA & Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. Journal of Acquired Immune Deficiency Syndromes 2003; 32:287-291.
15. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M & van der Ende ME. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clinical Pharmacokinetics 2003; 42:599-605.
16. Back D, Blaschke T, Boucher C, Burger D, Fletcher C, Flexner C, Gerber J, Hapiro J; the Editorial Board of HIVpharmacology.com. Optimising TDM in HIV Clinical Care. A practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents, version 1.0 (April 2003) Available at: www.hivpharmacology.com (last accessed: 26 September 2005).
17. Orrell CJ, Geel J, Pitt JA, Dyk MV & Wood R. Effect of fluconazole on nevirapine pharmacokinetics. The XV International AIDS Conference. 11-16 July 2004. Bangkok, Thailand. Abstract TuPeB4606 and oral presentation WeOrB1239.
18. Dean GL, Back DJ & de Ruiter A. Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999; 13:2489-2490.
19. Havlir D Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D & Myers M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. The Journal of Infectious Diseases 1995; 171:537-545.
20. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard D, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM & 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
21. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P & Copper DA. Risk or severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17:2191-2199.
22. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS & Xu DZ. Chronic hepatitis B virus infection in Asian countries. Journal of Gastroenterology and Hepatology 2000; 15:1356-1361.
23. de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, Gorp EC & Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort or HIV-1-infected individuals. British Journal of Clinical Pharmacology 2002; 54:378-385.
24. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S & Lallemant M. Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. The New England Journal of Medicine 2004; 351:229-240.
25. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE & Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-contaming antiretroviral therapy: role or hepatitis C and B infections. Hepatology 2002; 35:182-189.
26. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasin S, Prasithsirikul W, Sankote J, Mahanontharit A & Ruxrungtham K. Efavirenz levels and 4-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19:1481-1486.
27. Patel A, Patel K, Patel J, Shah N, Patel B & Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. Journal of Acquired Immune Deficiency Syndromes 2004; 37:1166-1169.
28. Stocrin. Summary of product characteristics; 2002 [cited: 2005 June]. Available from: http://www.emea.eu.int/humandocs/Humans/EPAR/Stocrin/Stocrin.htm
29. Viramune product information; 05/01/05 Viramune-H-C7183-II-45-PI; 2005 [cited: 2005 June]. Available from: http://www.ernea.eu.int/humandocs/Hurnans/ EPAR/viramune/viramune.htm
30. Roche Pharmaceuticals. Drug-induced hepatitis with marked transaminase elevations has been observed in healthy volunteers receiving rifampin 600 mg once daily in combination with ritonavir 100 mg/saquinavir 1000 mg, twice daily (ritonavir boosted saquinavir); 2005 [cited 2005 October 7]. Available from: http://www.fda.gov/medwatch/SAFETY/2005/Saquinavir-Rifampin_deardoc_Feb05.pdf